Trachoma Elimination Follow-up

Learn more about:
Related Clinical Trial
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Azithromycin Reduction to Reach Elimination of Trachoma Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Modified Instrumentation for Surgery to Correct Trichiasis Smartphone App for Taking Images of Conjunctivae Water Uptake for Health in Amhara Pilot A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Safety and Immunogenicity of a Chlamydia Vaccine CTH522 Fluorometholone as Ancillary Therapy for TT Surgery Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Trachoma Elimination Follow-up Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Azithromycin in Control of Trachoma II Sanitation, Water, and Instruction in Face-washing for Trachoma I/II Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders Trachoma Elimination Study by Focused Antibiotic (TESFA) Kebele Elimination of Trachoma for Ocular Health A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Trachoma Amelioration in Northern Amhara (TANA) Tripartite International Research for the Elimination of Trachoma Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Partnership for Rapid Elimination of Trachoma Nepal Elimination of Trachoma Study Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania

Brief Title

Trachoma Elimination Follow-up

Official Title

Trachoma Elimination With Repeated Mass Azithromycin Treatments

Brief Summary

      The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large
      part by mass oral azithromycin distributions. It is not clear how frequently or for how long
      these treatments are necessary. Here we assess the frequency and duration of treatment.

Detailed Description

      40 villages in the Gurage Zone of Ethiopia were randomly assigned to biannual treatment,
      annual treatment, and a single treatment. Each treatment consisted of a single dose of oral
      azithromycin to the entire population over the age of 1 year (when the study was started,
      azithromycin had not yet been approved for ages below 1 year). We assess the prevalence the
      ocular chlamydia that causes trachoma in the peak prevalence age of 1-5 years at baseline,
      and 2, 6, 12, 18, and 24 months post treatment. An extension of the study monitors infection
      at 30 and 36 months post treatment. Untreated villages from the same area are enrolled in a
      step-wedge design to assess the presence of a secular trend. A random sample of those not
      within the 1-5 year old age group are examined to assess the prevalence of infection in the
      entire community.

Study Phase

Phase 4

Study Type


Primary Outcome

The prevalence of ocular chlamydia infection in a village as determined by PCR

Secondary Outcome

 Clinical active trachoma, as determined by the WHO simplified grading system, by village




Mass treatment with oral azithromycin to an entire village


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2003

Completion Date

April 2005

Primary Completion Date

April 2005

Eligibility Criteria

        Inclusion Criteria:

        Age 1 to 5 years old in a village in the Gurage zone with endemic trachoma

        Exclusion Criteria:

        Refusal of village chief (for village inclusion), or refusal of parent or guardian (for
        individual inclusion)




1 Year - N/A

Accepts Healthy Volunteers



Thomas M Lietman, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

University of California, San Francisco

Study Sponsor

Thomas M Lietman, MD, Principal Investigator, Proctor Foundation, UCSF

Verification Date

July 2015